Catching you up on the week of September 8–14, 2025: the trial milestones, regulatory moves, and business developments shaping psychedelic medicine right now.
Cybin Inc. (CYBN): Cybin completes enrollment in Phase 2 study of CYB004 for generalized anxiety disorder
Cybin finished enrolling its Phase 2 trial of CYB004, a proprietary deuterated DMT candidate, in patients with generalized anxiety disorder. The study enrolled 36 participants and assesses safety and efficacy at 12 weeks after the first dose, with topline data reaffirmed for the first quarter of 2026. The milestone keeps Cybin's second clinical program on schedule alongside its lead CYB003 depression asset.
Source: ir.cybin.com
Sector coverage (AbbVie / Gilgamesh, Compass Pathways) (CMPS): STAT examines big pharma's growing appetite for psychedelic drugs
A STAT feature analyzed why large drugmakers are warming to psychedelics after AbbVie's late-August agreement to buy Gilgamesh Pharmaceuticals' bretisilocin for up to $1.2 billion, the first purchase of an investigational psychedelic by a major pharma company. Compass Pathways CEO Kabir Nath called the deal validation for the sector. The piece framed a shift in sentiment that investors in public names like Compass, Cybin and atai were watching closely.
Source: statnews.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.